{"symbol":"BEEC","attribute_content":[],"id":"2121","alternate_names":["Bladder exstrophy and epispadias complex","Exstrophy of the bladder-epispadias"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0017919\"}","{\"db\":\"Orphanet\",\"id\":\"322\"}","{\"db\":\"Orphanet\",\"id\":\"93930\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2207\",\"ref_field\":\"gard_id\"}","{\"db\":\"Orphanet\",\"id\":\"322\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"600057\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Exstrophy-epispadias complex","type":"Disease","gard_id":"2207","keywords":[],"medgen_id":"C1838703","alternate_symbols":[]}
{"symbol":"CTRCT2","attribute_content":[],"id":"696","alternate_names":["CATARACT 2, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA","CATARACT 2, NUCLEAR","CATARACT 2, NUCLEAR, WITH MICROCORNEA","CATARACT 2, ZONULAR PULVERULENT","Cataract, Coppock-like"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"604307\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"91492\"}","{\"db\":\"OMIM\",\"id\":\"604307\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CATARACT 2, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA\"}","{\"db\":\"OMIM\",\"id\":\"123680.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CATARACT 2, NUCLEAR\"}","{\"db\":\"OMIM\",\"id\":\"123680.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CATARACT 2, NUCLEAR, WITH MICROCORNEA\"}","{\"db\":\"OMIM\",\"id\":\"123680.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CATARACT 2, NUCLEAR, WITH MICROCORNEA\"}","{\"db\":\"OMIM\",\"id\":\"123680.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CATARACT 2, ZONULAR PULVERULENT\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cataract%2C+coppock-like/7919\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cataract, Coppock-like\"}","{\"db\":\"OMIM\",\"id\":\"604307\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CCL\"}","{\"db\":\"OMIM\",\"id\":\"604307\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Cataract 2, multiple types","type":"Disease","keywords":[],"medgen_id":"C4721890","alternate_symbols":["CCL"]}
{"symbol":"RHUC2","attribute_content":[],"id":"2402","alternate_names":["HYPOURICEMIA, RENAL, 2, AUTOSOMAL DOMINANT","HYPOURICEMIA, RENAL, 2, AUTOSOMAL RECESSIVE"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012793\"}","{\"db\":\"OMIM\",\"id\":\"612076\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"606142.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOURICEMIA, RENAL, 2, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606142.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOURICEMIA, RENAL, 2, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606142.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOURICEMIA, RENAL, 2, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606142.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOURICEMIA, RENAL, 2, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"606142.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOURICEMIA, RENAL, 2, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"606142.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOURICEMIA, RENAL, 2, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"606142.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOURICEMIA, RENAL, 2, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"606142.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOURICEMIA, RENAL, 2, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"606142.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOURICEMIA, RENAL, 2, AUTOSOMAL RECESSIVE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Renal+hypouricemia+2/9217\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612076\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Renal hypouricemia 2","type":"Disease","keywords":[],"medgen_id":"C2677549","alternate_symbols":[]}
{"symbol":"RAFQS","attribute_content":[],"id":"16522","alternate_names":["RAFIQ SYNDROME"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013624\"}","{\"db\":\"OMIM\",\"id\":\"614202\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"88616\"}","{\"db\":\"OMIM\",\"id\":\"604346.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RAFIQ SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"604346.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RAFIQ SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"604346.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RAFIQ SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"614202\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RAFIQ SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"614202\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MRT15\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Mental+retardation%2C+autosomal+recessive+15/8837\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614202\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Mental retardation, autosomal recessive 15","type":"Disease","keywords":[],"medgen_id":"C3280127","alternate_symbols":["MRT15"]}
{"symbol":"HYRPRO1","attribute_content":[],"id":"1742","alternate_names":["Hyperprolinemia type 1","PROLINE OXIDASE DEFICIENCY"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009400\"}","{\"db\":\"OMIM\",\"id\":\"239500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"419\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009400\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hyperprolinemia type 1\"}","{\"db\":\"Orphanet\",\"id\":\"419\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hyperprolinemia type 1\"}","{\"db\":\"OMIM\",\"id\":\"239500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PROLINE OXIDASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"239500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HPI\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Proline+dehydrogenase+deficiency/9171\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"61071003\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"239500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Proline dehydrogenase deficiency","type":"Disease","keywords":[],"medgen_id":"C0268529","alternate_symbols":["HPI"]}
{"attribute_content":[],"id":"40886","alternate_names":["MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 13"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032618\"}","{\"db\":\"OMIM\",\"id\":\"618235\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"602137.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 13\"}","{\"db\":\"OMIM\",\"id\":\"602137.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 13\"}","{\"db\":\"OMIM\",\"id\":\"602137.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 13\"}","{\"db\":\"OMIM\",\"id\":\"602137.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 13\"}","{\"db\":\"OMIM\",\"id\":\"618235\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 13\"}","{\"db\":\"OMIM\",\"id\":\"618235\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MC1DN13\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0032618\",\"ref_field\":\"name\"}"],"name":"Mitochondrial complex 1 deficiency, nuclear type 13","type":"Disease","keywords":[],"medgen_id":"C4748770","alternate_symbols":["MC1DN13"]}
{"symbol":"SEMDM","attribute_content":[],"id":"4196","alternate_names":["Missouri type of spondyloepimetaphyseal dysplasia","SEMD Missouri type"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011198\"}","{\"db\":\"OMIM\",\"id\":\"602111\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1040\"}","{\"db\":\"Orphanet\",\"id\":\"93356\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10618\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spondyloepimetaphyseal+dysplasia+Missouri+type/6811\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"602111\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Spondyloepimetaphyseal dysplasia, Missouri type","type":"Disease","gard_id":"10618","keywords":[],"medgen_id":"C1865832","alternate_symbols":[]}
{"symbol":"RCCP","attribute_content":[],"id":"25826","alternate_names":["Papillary renal carcinoma, malignant - (subtype)","Papillary renal cell carcinoma, bilateral - (subtype)","Papillary renal cell carcinoma, familial - (subtype)","Papillary renal cell carcinoma, multiple - (subtype)","Papillary renal cell carcinoma, sporadic - (subtype)"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006766\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006776\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006766\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"733608000\",\"ref_field\":\"name\"}"],"name":"Papillary renal cell carcinoma","type":"Disease","keywords":[],"medgen_id":"C1306837","alternate_symbols":[]}
{"attribute_content":[],"id":"892","alternate_names":["CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE 2","Calcium gout","Calcium gout, familial","Calcium pyrophosphate arthropathy","Calcium pyrophosphate arthropathy, familial","Calcium pyrophosphate dihydrate deposition disease","Chondrocalcinosis 2","Chondrocalcinosis familial articular","Pseudogout, familial"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007319\"}","{\"db\":\"OMIM\",\"id\":\"118600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1416\"}","{\"db\":\"OMIM\",\"id\":\"118600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE 2\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Chondrocalcinosis+2/1359\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Chondrocalcinosis 2\"}","{\"db\":\"OMIM\",\"id\":\"118600\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CCAL2\"}","{\"db\":\"OMIM\",\"id\":\"118600\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CPPDD\"}","{\"db\":\"OMIM\",\"id\":\"118600\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CPPDD2 CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1292\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007319\",\"ref_field\":\"name\"}"],"name":"Familial calcium pyrophosphate deposition","type":"Disease","gard_id":"1292","keywords":[],"medgen_id":"C0856830","alternate_symbols":["CCAL2","CPPDD","CPPDD2 CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE"]}
{"symbol":"WMS2","attribute_content":[],"id":"5118","alternate_names":["Glaucoma, Ectopia, Microspherophakia, Stiff joints and Short stature syndrome","MESODERMAL DYSMORPHODYSTROPHY, CONGENITAL","Weill-Marchesani Syndrome, Autosomal Dominant"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012013\"}","{\"db\":\"OMIM\",\"id\":\"608328\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2084\"}","{\"db\":\"OMIM\",\"id\":\"608328\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MESODERMAL DYSMORPHODYSTROPHY, CONGENITAL\"}","{\"db\":\"OMIM\",\"id\":\"608328\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"GEMSS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2452\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Weill-Marchesani+syndrome+2/9473\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1114\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"608328\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Weill-Marchesani syndrome 2","type":"Disease","gard_id":"2452","keywords":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301293\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1114\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1869115","alternate_symbols":["GEMSS"],"public_definition":"Weill-Marchesani syndrome (WMS) is a connective tissue disorder characterized by abnormalities of the lens of the eye, proportionate short stature, brachydactyly, and joint stiffness. The ocular problems, typically recognized in childhood, include microspherophakia (small spherical lens), myopia secondary to the abnormal shape of the lens, ectopia lentis (abnormal position of the lens), and glaucoma, which can lead to blindness. Height of adult males is 142-169 cm; height of adult females is 130-157 cm. Autosomal recessive and autosomal dominant WMS cannot be distinguished by clinical findings alone."}
{"symbol":"WMS1","attribute_content":[],"id":"5119","alternate_names":["MESODERMAL DYSMORPHODYSTROPHY, CONGENITAL","Weill-Marchesani Syndrome, Autosomal Recessive","Weill-Marchesani syndrome 1, recessive"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010194\"}","{\"db\":\"OMIM\",\"id\":\"277600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3449\"}","{\"db\":\"OMIM\",\"id\":\"277600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MESODERMAL DYSMORPHODYSTROPHY, CONGENITAL\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Weill-Marchesani+syndrome+1/9472\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1114\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"277600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Weill-Marchesani syndrome 1","type":"Disease","keywords":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301293\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1114\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C4552002","alternate_symbols":[],"public_definition":"Weill-Marchesani syndrome (WMS) is a connective tissue disorder characterized by abnormalities of the lens of the eye, proportionate short stature, brachydactyly, and joint stiffness. The ocular problems, typically recognized in childhood, include microspherophakia (small spherical lens), myopia secondary to the abnormal shape of the lens, ectopia lentis (abnormal position of the lens), and glaucoma, which can lead to blindness. Height of adult males is 142-169 cm; height of adult females is 130-157 cm. Autosomal recessive and autosomal dominant WMS cannot be distinguished by clinical findings alone."}
{"symbol":"PCH1B","attribute_content":[],"id":"17017","alternate_names":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013853\"}","{\"db\":\"OMIM\",\"id\":\"614678\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2254\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK236968\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614678\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Pontocerebellar hypoplasia, type 1b","type":"Disease","keywords":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"25144110\",\"@Source\":\"PubMed\"},{\"$\":\"NBK236968\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C3553449","alternate_symbols":[],"public_definition":"EXOSC3 pontocerebellar hypoplasia (EXOSC3-PCH) is characterized by abnormalities in the posterior fossa and degeneration of the anterior horn cells. At birth, skeletal muscle weakness manifests as hypotonia (sometimes with congenital joint contractures) and poor feeding. In persons with prolonged survival, spasticity, dystonia, and seizures become evident. Within the first year of life respiratory insufficiency and swallowing difficulties are common. Intellectual disability is severe. Life expectancy ranges from a few weeks to adolescence. To date, 82 individuals (from 58 families) with EXOSC3-PCH have been described."}
{"symbol":"PRLTS1","attribute_content":[],"id":"15884","alternate_names":["GONADAL DYSGENESIS, XX TYPE, WITH DEAFNESS","OVARIAN DYSGENESIS WITH SENSORINEURAL DEAFNESS"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009300\"}","{\"db\":\"OMIM\",\"id\":\"233400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2855\"}","{\"db\":\"OMIM\",\"id\":\"233400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GONADAL DYSGENESIS, XX TYPE, WITH DEAFNESS\"}","{\"db\":\"OMIM\",\"id\":\"233400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OVARIAN DYSGENESIS WITH SENSORINEURAL DEAFNESS\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK242617\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"233400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Perrault syndrome 1","type":"Disease","keywords":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"25254289\",\"@Source\":\"PubMed\"},{\"$\":\"NBK242617\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C4551721","alternate_symbols":[],"public_definition":"Perrault syndrome is characterized by sensorineural hearing loss (SNHL) in males and females and ovarian dysfunction in females. SNHL is bilateral and ranges from profound with prelingual (congenital) onset to moderate with early-childhood onset. When onset is in early childhood, hearing loss can be progressive. Ovarian dysfunction ranges from gonadal dysgenesis (absent or streak gonads) manifesting as primary amenorrhea to primary ovarian insufficiency (POI) defined as cessation of menses before age 40 years. Fertility in affected males is reported as normal (although the number of reported males is limited). Neurologic features described in some individuals with Perrault syndrome include learning difficulties and developmental delay, cerebellar ataxia, and motor and sensory peripheral neuropathy."}
{"symbol":"MRMV1","attribute_content":[],"id":"2955","alternate_names":["BIMANUAL SYNERGIA","MIRROR MOVEMENTS 1 AND/OR AGENESIS OF THE CORPUS CALLOSUM"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008002\"}","{\"db\":\"OMIM\",\"id\":\"157600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"238722\"}","{\"db\":\"OMIM\",\"id\":\"157600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BIMANUAL SYNERGIA\"}","{\"db\":\"OMIM\",\"id\":\"120470.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MIRROR MOVEMENTS 1 AND/OR AGENESIS OF THE CORPUS CALLOSUM\"}","{\"db\":\"OMIM\",\"id\":\"120470.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MIRROR MOVEMENTS 1 AND/OR AGENESIS OF THE CORPUS CALLOSUM\"}","{\"db\":\"OMIM\",\"id\":\"120470.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MIRROR MOVEMENTS 1 AND/OR AGENESIS OF THE CORPUS CALLOSUM\"}","{\"db\":\"OMIM\",\"id\":\"120470.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MIRROR MOVEMENTS 1 AND/OR AGENESIS OF THE CORPUS CALLOSUM\"}","{\"db\":\"OMIM\",\"id\":\"120470.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MIRROR MOVEMENTS 1 AND/OR AGENESIS OF THE CORPUS CALLOSUM\"}","{\"db\":\"OMIM\",\"id\":\"120470.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MIRROR MOVEMENTS 1 AND/OR AGENESIS OF THE CORPUS CALLOSUM\"}","{\"db\":\"OMIM\",\"id\":\"120470.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MIRROR MOVEMENTS 1 AND/OR AGENESIS OF THE CORPUS CALLOSUM\"}","{\"db\":\"OMIM\",\"id\":\"157600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MIRROR MOVEMENTS 1 AND/OR AGENESIS OF THE CORPUS CALLOSUM\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK279760\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"157600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Mirror movements 1","type":"Disease","keywords":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"25763452\",\"@Source\":\"PubMed\"},{\"$\":\"NBK279760\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1834870","alternate_symbols":[],"public_definition":"The disorder of congenital mirror movements (CMM) is characterized by early-onset, obvious mirror movements (involuntary movements of one side of the body that mirror intentional movements on the opposite side) in individuals who typically have no other clinical signs or symptoms. Although mirror movements vary in severity, most affected individuals have strong and sustained mirror movements of a lesser amplitude than the corresponding voluntary movements. Mirror movements usually persist throughout life, without deterioration or improvement, and are not usually associated with subsequent onset of additional neurologic manifestations. However, a subset of affected individuals with a heterozygous pathogenic variant in DCC may have CMM with abnormalities of the corpus callosum and concomitant cognitive and/or neuropsychiatric issues."}
{"symbol":"MRMV2","attribute_content":[],"id":"16848","alternate_names":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013790\"}","{\"db\":\"OMIM\",\"id\":\"614508\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"238722\"}","{\"db\":\"Genetic Alliance\",\"id\":\"MIRROR+MOVEMENTS+2/8894\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK279760\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614508\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Mirror movements 2","type":"Disease","keywords":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"25763452\",\"@Source\":\"PubMed\"},{\"$\":\"NBK279760\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C3281089","alternate_symbols":[],"public_definition":"The disorder of congenital mirror movements (CMM) is characterized by early-onset, obvious mirror movements (involuntary movements of one side of the body that mirror intentional movements on the opposite side) in individuals who typically have no other clinical signs or symptoms. Although mirror movements vary in severity, most affected individuals have strong and sustained mirror movements of a lesser amplitude than the corresponding voluntary movements. Mirror movements usually persist throughout life, without deterioration or improvement, and are not usually associated with subsequent onset of additional neurologic manifestations. However, a subset of affected individuals with a heterozygous pathogenic variant in DCC may have CMM with abnormalities of the corpus callosum and concomitant cognitive and/or neuropsychiatric issues."}
{"symbol":"SCA7","attribute_content":[],"id":"4183","alternate_names":["ADCA type 2","ADCA, TYPE II","AUTOSOMAL DOMINANT CEREBELLAR ATAXIA, TYPE II","Autosomal dominant cerebellar ataxia type 2","OLIVOPONTOCEREBELLAR ATROPHY III","OPCA III","Olivopontocerebellar atrophy 3"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"164500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"94147\"}","{\"db\":\"OMIM\",\"id\":\"164500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADCA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"164500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AUTOSOMAL DOMINANT CEREBELLAR ATAXIA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"164500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OLIVOPONTOCEREBELLAR ATROPHY III\"}","{\"db\":\"OMIM\",\"id\":\"164500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPCA III\"}","{\"db\":\"OMIM\",\"id\":\"164500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"OPCA3\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1256\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"164500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Spinocerebellar ataxia 7","type":"Disease","keywords":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301433\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1256\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301317\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1138\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20050888\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EFNS/ENS, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24418350\",\"@Source\":\"PubMed\"}}]}","medgen_id":"C0752125","alternate_symbols":["OPCA3"],"public_definition":"Spinocerebellar ataxia type 7 (SCA7) comprises a phenotypic spectrum ranging from adolescent- or adult-onset progressive cerebellar ataxia and cone-rod retinal dystrophy to infantile or early-childhood onset with multiorgan failure, an accelerated course, and early death. Anticipation in this nucleotide repeat disorder may be so dramatic that within a family a child with infantile or early-childhood onset may be diagnosed with what is thought to be an unrelated neurodegenerative disorder years before a parent or grandparent with a CAG repeat expansion becomes symptomatic. In adolescent-onset SCA7, the initial manifestation is typically impaired vision, followed by cerebellar ataxia. In those with adult onset, progressive cerebellar ataxia usually precedes the onset of visual manifestations. While the rate of progression varies in these two age groups, the eventual result for almost all affected individuals is loss of vision, severe dysarthria and dysphagia, and a bedridden state with loss of motor control."}
{"attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000505068\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507480\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507942\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522527\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000568367\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000591289\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000246735\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260631\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520063\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520447\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528528\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552214\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556520\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000558532\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000325415\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000512526\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528276\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528500\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528536\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556501\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000514924\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520414\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528516\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551442\"}]}"],"id":"1790","alternate_names":["Alpha-galactosidase A deficiency","Anderson-Fabry disease","Angiokeratoma corporis diffusum","Angiokeratoma, diffuse","Ceramide trihexosidase deficiency","Ceramide trihexosidosis","Fabry syndrome","Fabry's disease","GLA deficiency","Hereditary dystopic lipidosis"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010526\"}","{\"db\":\"OMIM\",\"id\":\"301500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiokeratoma corporis diffusum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fabry+Disease/2690\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"16652001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6400\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fabry-disease\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1292\",\"ref_field\":\"public_definition\"}"],"name":"Fabry disease","type":"Disease","disease_mechanism":"Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A.","gard_id":"6400","keywords":[],"content":"{\"Citation\":[{\"@Type\":\"general\",\"ID\":{\"$\":\"3009617\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301469\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1292\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"HFSA, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20610207\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12735292\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Eng et al., 2006\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16980809\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Salviati et al, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2869001\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21934708\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHA/ASA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25355838\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23860966\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","medgen_id":"C0002986","alternate_symbols":[],"public_definition":"Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (a-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% a-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, males with greater than 1% a-Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack."}
